Published in Blood Weekly, November 30th, 2006
MB07811, Metabasis' fifth internally discovered product candidate to enter human clinical trials, uses the company's proprietary HepDirect prodrug technology to target a beta-subtype-selective thyroid hormone receptor (TRB) agonist to the liver to reduce serum cholesterol (LDL) and triglycerides (TGs). The company believes that this drug class has the potential to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.